PubMed · 13534757
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Y Nishizawa. 1958. [Lymphocyte studies].. https://pubmed.ncbi.nlm.nih.gov/13534757/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
PURPOSE: To determine whether cancers of the prostate transition zone (TZ) possess a unique metabolic pattern by which they may be identified at proton magnetic resonance (MR) spectroscopic imaging. MATERIALS AND METHODS: Findings in 40 patients who underwent combined endorectal MR imaging and hydrogen 1 MR spectroscopic imaging before radical prostatectomy and who had TZ tumor identified subsequently at step-section pathologic analysis were retrospectively reviewed. Within this population, a subset of 16 patients whose TZ tumor had a largest diameter of 1 cm or greater and was included in the MR spectroscopic imaging excitation volume was identified. In these 16 patients, the ratios of choline-containing compounds (Cho) and creatine/phosphocreatine (Cr) to citrate (Cit) (ie, [Cho + Cr]/Cit), Cho/Cr, and Cho/Cit were compared in tumor and control tissues. The presence of only Cho and the absence of all metabolites were also assessed. RESULTS: The mean values of (Cho + Cr)/Cit, Cho/Cr, and Cho/Cit were different between TZ cancer and control tissues (P =.001, P =.003, and P =.001, respectively; Wilcoxon signed rank test). Nine (56%) of 16 patients had at least one tumor voxel in which Cho comprised the only detectable peak, while no control voxels showed only Cho (P =.008, McNemar test). The percentage of voxels in which no metabolites were detected did not differ between tumor and control tissues (P =.134, McNemar test). CONCLUSION: TZ cancer has a metabolic profile that is different from that of benign TZ tissue; however, the broad range of metabolite ratios observed in TZ cancer precludes the use of a single ratio to differentiate TZ cancer from benign TZ tissue.
In the yeast Saccharomyces cerevisiae, the expression of phospholipid biosynthetic genes, including the INO1 gene (encoding inositol-1-phosphate synthase), is coordinately regulated by a cis-acting transcriptional element, UAS(INO) (inositol-sensitive upstream activating sequence). For this paper we studied the effect of SCS2 disruption on INO1 expression. SCS2 encodes a type II membrane protein and its deletion leads to inositol auxotrophy at temperatures above 34 degrees C. We found that the expression of the INO1 gene was reduced in the scs2Delta strain even when the cells were cultured under derepressing conditions for INO1 expression. However, the beta-galactosidase gene fused with the INO1 promoter region was expressed normally in the scs2Delta strain. The phospholipid composition of scs2Delta cells was not dramatically changed compared with wild-type cells at 28 degrees C, but the phosphatidylinositol level was reduced in scs2Delta cells cultured at 34 degrees C. In addition, elevated phosphatidylcholine synthesis through the CDP-choline pathway was observed in the scs2Delta strain, and the disruption of genes involved in the CDP-choline pathway rescued the INO1 expression defect of the scs2Delta strain. These results indicate that Scs2p can contribute to coordinated phospholipid metabolism including INO1 expression by regulating phosphatidylcholine synthesis through the CDP-choline pathway.
Explore the source record for details and available documents.